ARQ-151 Active for Atopic Dermatitis

"There is some evidence to support the efficacy of ARQ-151 Active, as it has reached Phase 3 in clinical trials. Additionally, there is sufficient data suggesting that ARQ-151 Active is safe for human use."

"This trial is specifically for children aged 2 to 5. In total, there are 110 clinical trials involving pediatric patients and 181 trials for elderly patients."

"The primary outcome of this study is IGA Success, which will be evaluated over the course of roughly Week 4. IGA Success is defined as a vIGA-AD score of 'clear' or 'almost clear' PLUS a 2-grade improvement from Baseline at Week 4. Secondary outcomes include The proportion of randomized subjects with a vIGA-AD score of 'Moderate' at randomization who attain IGA Success and the Proportion of patients with vIGA-AD score of 'clear' or 'almost clear'. The vIGA-AD is a static evaluation of qualitative overall AD severity. This"

"84 other locations are also running this trial, such as the Arcutis Clinical Site in Bellaire, Sacramento, and Frisco."

"This clinical trial is looking for 650 participants, between the ages of 2 and 5, who currently have dermatitis. It is important that participants also meet the following criteria: Informed consent by parent(s) or legal guardian as required by local laws., Males and females, ages 2 to 5 years old at time of signing Informed Consent (Screening) and at Baseline (Day 1)., Diagnosed with atopic dermatitis for at least 6 weeks, as determined by the Investigator. Stable disease for the past 4 weeks with no significant flares in atopic dermatitis before screening., In good health as judged by"